Prospective and clinical validation of ALK immunohistochemistry: Results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

Annals of Oncology

Volumn 27, Issue 1, 2016, Pages 185-192

  Takeuchi, Kengo ^a,b   Togashi, Y ^a,b   Kamihara, Y ^c   Fukuyama, T ^c   Yoshioka, H ^d   Inoue, A ^e   Katsuki, H ^c   Kiura, K ^f   Nakagawa, K ^g   Seto, T ^h   Maemondo, M ⁱ   Hida, T ^j   Harada, M ^k   Ohe, Y ^l   Nogami, N ^m   Yamamoto, N ⁿ   Nishio, M ^o   Tamura, T ^p  

^a Pathology Project for Molecular Targets   (Japan)

^b CANCER INSTITUTE   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^d KURASHIKI CENTRAL HOSPITAL   (Japan)

^e TOHOKU UNIVERSITY HOSPITAL   (Japan)

^f OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^g KINDAI UNIVERSITY HOSPITAL   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ Miyagi Cancer Center   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

^k HOKKAIDO CANCER CENTER   (Japan)

^l NATIONAL CANCER CENTER HOSPITAL   (Japan)

^m NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

ⁿ SHIZUOKA CANCER CENTER   (Japan)

^o CANCER INSTITUTE HOSPITAL   (Japan)

^p ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

more..

Author keywords

Alectinib; ALK; Companion diagnostics; FISH; Immunohistochemistry; Iscore

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; ONCOPROTEIN; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX RATIO; TREATMENT RESPONSE; TUMOR VOLUME; ADENOCARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBAZOLES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PIPERIDINES; PROSPECTIVE STUDIES; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960099751     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv501     Document Type: Article

References (16)

1. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
2. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
3. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008; 14: 6618-6624.
4. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-3149.
5. Kodama T, Tsukaguchi T, Yoshida M et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014; 351: 215-221.
6. Seto T, Kiura K, Nishio M et al. CH5424802 (RO5424802) for patients with ALKrearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013; 14: 590-598.
7. Takamochi K, Takeuchi K, Hayashi T et al. A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One 2013; 8: e69794.
8. Takeuchi K. Interpretation of anti-ALK immunohistochemistry results. J Thorac Oncol 2013; 8: e67-e68.
9. Ohe Y, Nishio M, Kiura K et al. A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+NSCLC) patients ( pts): updates on progression free survival (PFS) and safety results from AF-001JP. J Clin Oncol 2015; 33(suppl: abstr 8061).
10. Takeuchi K, Soda M, Togashi Y et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-381.
11. Togashi Y, Soda M, Sakata S et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012; 7: e31323.
12. Yoshida A, Tsuta K, Nitta H et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011; 6: 1677-1686.
13. Ren S, Hirsch FR, Varella-Garcia M et al. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol 2014; 9: e21-e23.
14. Gainor JF, Varghese AM, Ou SH et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013; 19: 4273-4281.
15. Murakami Y, Mitsudomi T, Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol 2012; 2: 24.
16. Peled N, Palmer G, Hirsch FR et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012; 7: e14-e16.